New Market Report: PharmaPoint: Parkinson's Disease

Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson's disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. It is expected that the prevalence of Parkinson's disease in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and Brazil will increase from 3.2m people in 2012 to 4.3m people in 2022, driven by an aging population in all markets. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.

Full Report Details at
- http://www.fastmr.com/prod/1052804_pharmapoint_parkinsons.aspx?afid=301

Highlights

Key Questions Answered

* According to KOLs, what are the most important unmet needs in PD? Will these needs be addressed by pipeline agents? What needs will remain by the end of the forecast period in 2022?
* With the recent launch of Xadago and Rytary and an additional four drugs in the late-stage pipeline, which products are forecast to generate the highest sales over 2012-2022?
* What corporate strategies have been employed for recent product launches? What opportunities remain for new entrants?
* An aging population is expected to increase prevalence of PD in all markets from 2012-2022. How will epidemiological changes impact the growth of the future PD market?
* What governmental developments are likely to affect reimbursement and generic erosion of PD drugs? What type of impact will this have on the markets covered over the forecast period?

Key Findings

* Population increases, especially in the elderly, will be a key driving force in the global PD market.
* With several small biotech and pharmaceutical companies involved in mid-stage development of PD products, there will be ample opportunity for partnerships with Big Pharma.
* Levodopa based therapy will remain the gold standard of care with advancements in administration, including the introduction of slow-release formulations and an emergency use inhaler.
* Several unmet needs are expected to remain after the forecast period, as advancements in the control of non-motor symptoms and in the development of disease-modifying therapies are lagging.

Scope

* Overview of Parkinson's disease, including etiology, pathophysiology, motor and non-motor symptoms, and quality of life.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update
- PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update
- PharmaPoint: HER2-Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2023
- PharmaPoint: Macular Edema and Macular Degeneration - Global Drug Forecast and Market Analysis to 2023
- PharmaPoint: Alzheimer's Disease - Global Drug Forecast and Market Analysis to 2023